Adult Gliosarcoma
78
0
1
56
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
38 trials with published results (49%)
Research Maturity
56 completed trials (72% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
23.1%
18 terminated out of 78 trials
75.7%
-10.8% vs benchmark
0%
0 trials in Phase 3/4
68%
38 of 56 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 56 completed trials
Clinical Trials (78)
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma